{"id":70897,"date":"2026-07-29T18:42:49","date_gmt":"2026-07-29T10:42:49","guid":{"rendered":"https:\/\/flcube.com\/?p=70897"},"modified":"2026-07-29T18:42:50","modified_gmt":"2026-07-29T10:42:50","slug":"ribo-life-sciences-sirna-therapy-vortosiran-receives-ema-approval-for-stroke-prevention-trial-in-atrial-fibrillation-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70897","title":{"rendered":"Ribo Life Science&#8217;s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Ribo Life Science<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/6938:HKG\">HKG: 6938<\/a>) announced that its <strong>small interfering RNA (siRNA) therapy vortosiran (BD4059)<\/strong> has received <strong>clinical trial approval<\/strong> from the <strong>European Medicines Agency (EMA)<\/strong> for <strong>stroke prevention in patients with atrial fibrillation (SPAF)<\/strong>, leveraging strong human genetic evidence supporting Factor XI (FXI) inhibition as a safer antithrombotic strategy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ribo Life Science (HKG: 6938)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Vortosiran (BD4059)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>European Medicines Agency (EMA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Stroke prevention in atrial fibrillation (SPAF)<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>RiboGalSTAR liver-targeting technology<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>28 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<h3 id=\"h-sirna-technology-platform\" class=\"wp-block-heading\">siRNA Technology Platform<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Class:<\/strong> <strong>GalNAc-conjugated siRNA<\/strong> drug candidate<\/li>\n\n\n\n<li><strong>Platform Origin:<\/strong> Independently developed using <strong>RiboGalSTAR liver-targeting technology<\/strong><\/li>\n\n\n\n<li><strong>Delivery System:<\/strong> GalNAc conjugation enables specific hepatocyte targeting and extended half-life<\/li>\n\n\n\n<li><strong>Dosing Advantage:<\/strong> Potential for infrequent subcutaneous administration due to siRNA durability<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-target-biology-amp-mechanism\" class=\"wp-block-heading\">Target Biology &amp; Mechanism<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Target:<\/strong> <strong>Factor XI (FXI)<\/strong> synthesis inhibition<\/li>\n\n\n\n<li><strong>Pathway:<\/strong> Blocks <strong>intrinsic coagulation pathway<\/strong> to achieve antithrombotic activity<\/li>\n\n\n\n<li><strong>Genetic Validation:<\/strong> Strong human genetic evidence shows individuals with naturally lower FXI levels have reduced thrombotic risk without increased bleeding<\/li>\n\n\n\n<li><strong>Safety Hypothesis:<\/strong> Selective FXI inhibition may provide antithrombotic efficacy while preserving hemostatic function<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-rationale-amp-unmet-need\" class=\"wp-block-heading\">Clinical Rationale &amp; Unmet Need<\/h2>\n\n\n\n<h3 id=\"h-atrial-fibrillation-stroke-prevention\" class=\"wp-block-heading\">Atrial Fibrillation Stroke Prevention<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Millions of atrial fibrillation patients worldwide requiring anticoagulation<\/li>\n\n\n\n<li><strong>Current Limitations:<\/strong> Existing anticoagulants (warfarin, DOACs) carry significant bleeding risks<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Need for safer antithrombotic agents that maintain efficacy while reducing hemorrhagic complications<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Multi-billion dollar anticoagulation market with premium pricing for improved safety profiles<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-fxi-inhibition-advantages\" class=\"wp-block-heading\">FXI Inhibition Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bleeding Risk:<\/strong> Genetic evidence suggests FXI deficiency does not increase spontaneous bleeding<\/li>\n\n\n\n<li><strong>Therapeutic Window:<\/strong> Potentially wider safety margin compared to traditional anticoagulants<\/li>\n\n\n\n<li><strong>Mechanistic Specificity:<\/strong> Targets pathological thrombosis without affecting physiological hemostasis<\/li>\n\n\n\n<li><strong>Clinical Validation:<\/strong> Multiple FXI inhibitors in development validate target biology<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-ribo-life-science\" class=\"wp-block-heading\">For Ribo Life Science<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Success validates RiboGalSTAR liver-targeting siRNA platform capabilities<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Opens pathway for additional siRNA candidates targeting hepatic-expressed proteins<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> EMA approval represents significant milestone for Chinese biotech company&#8217;s international strategy<\/li>\n\n\n\n<li><strong>Investor Confidence:<\/strong> Demonstrates ability to advance novel RNAi therapeutics through regulatory pathways<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FXI Race:<\/strong> Competing with antisense oligonucleotides (ASOs) and monoclonal antibodies targeting FXI<\/li>\n\n\n\n<li><strong>siRNA Differentiation:<\/strong> Potential dosing advantages over ASOs and antibodies due to extended duration of action<\/li>\n\n\n\n<li><strong>First-Mover Potential:<\/strong> Could become first siRNA-based antithrombotic if development progresses successfully<\/li>\n\n\n\n<li><strong>Partnership Value:<\/strong> Positive clinical data could attract global pharmaceutical partnerships<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-outlook\" class=\"wp-block-heading\">Development Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The EMA approval enables Ribo Life Science to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Initiate Phase I\/II trials<\/strong> in European SPAF patient populations<\/li>\n\n\n\n<li><strong>Generate clinical proof-of-concept<\/strong> for FXI inhibition via siRNA approach<\/li>\n\n\n\n<li><strong>Establish safety and efficacy profile<\/strong> compared to existing anticoagulants<\/li>\n\n\n\n<li><strong>Expand development<\/strong> into additional thrombotic indications based on initial results<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072801214_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072801214_c.\"><\/object><a id=\"wp-block-file--media-757db8da-002b-4627-bb63-a0bc4dd5f20d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072801214_c.pdf\">2026072801214_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072801214_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-757db8da-002b-4627-bb63-a0bc4dd5f20d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,4524,1725,64],"class_list":["post-70897","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-6938","tag-ribo-life-science","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ribo Life Science&#039;s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059) has received clinical trial approval from the European Medicines Agency (EMA) for stroke prevention in patients with atrial fibrillation (SPAF), leveraging strong human genetic evidence supporting Factor XI (FXI) inhibition as a safer antithrombotic strategy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70897\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ribo Life Science&#039;s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients\" \/>\n<meta property=\"og:description\" content=\"Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059) has received clinical trial approval from the European Medicines Agency (EMA) for stroke prevention in patients with atrial fibrillation (SPAF), leveraging strong human genetic evidence supporting Factor XI (FXI) inhibition as a safer antithrombotic strategy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70897\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T10:42:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-29T10:42:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70897#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70897\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ribo Life Science&#8217;s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients\",\"datePublished\":\"2026-07-29T10:42:49+00:00\",\"dateModified\":\"2026-07-29T10:42:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70897\"},\"wordCount\":488,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 6938\",\"Ribo Life Science\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70897#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70897\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70897\",\"name\":\"Ribo Life Science's siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-29T10:42:49+00:00\",\"dateModified\":\"2026-07-29T10:42:50+00:00\",\"description\":\"Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059) has received clinical trial approval from the European Medicines Agency (EMA) for stroke prevention in patients with atrial fibrillation (SPAF), leveraging strong human genetic evidence supporting Factor XI (FXI) inhibition as a safer antithrombotic strategy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70897#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70897\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70897#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ribo Life Science&#8217;s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ribo Life Science's siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients - Insight, China&#039;s Pharmaceutical Industry","description":"Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059) has received clinical trial approval from the European Medicines Agency (EMA) for stroke prevention in patients with atrial fibrillation (SPAF), leveraging strong human genetic evidence supporting Factor XI (FXI) inhibition as a safer antithrombotic strategy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70897","og_locale":"en_US","og_type":"article","og_title":"Ribo Life Science's siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients","og_description":"Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059) has received clinical trial approval from the European Medicines Agency (EMA) for stroke prevention in patients with atrial fibrillation (SPAF), leveraging strong human genetic evidence supporting Factor XI (FXI) inhibition as a safer antithrombotic strategy.","og_url":"https:\/\/flcube.com\/?p=70897","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-29T10:42:49+00:00","article_modified_time":"2026-07-29T10:42:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70897#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70897"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ribo Life Science&#8217;s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients","datePublished":"2026-07-29T10:42:49+00:00","dateModified":"2026-07-29T10:42:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70897"},"wordCount":488,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 6938","Ribo Life Science","RNAi \/ ASO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70897#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70897","url":"https:\/\/flcube.com\/?p=70897","name":"Ribo Life Science's siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-29T10:42:49+00:00","dateModified":"2026-07-29T10:42:50+00:00","description":"Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059) has received clinical trial approval from the European Medicines Agency (EMA) for stroke prevention in patients with atrial fibrillation (SPAF), leveraging strong human genetic evidence supporting Factor XI (FXI) inhibition as a safer antithrombotic strategy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70897#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70897"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70897#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ribo Life Science&#8217;s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70897"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70897\/revisions"}],"predecessor-version":[{"id":70899,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70897\/revisions\/70899"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}